CN104523817A - 一种用于治疗类风湿性关节炎的中药组合物 - Google Patents
一种用于治疗类风湿性关节炎的中药组合物 Download PDFInfo
- Publication number
- CN104523817A CN104523817A CN201510046858.6A CN201510046858A CN104523817A CN 104523817 A CN104523817 A CN 104523817A CN 201510046858 A CN201510046858 A CN 201510046858A CN 104523817 A CN104523817 A CN 104523817A
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- rheumatoid arthritis
- medicine composition
- treatment
- prepared
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 64
- 239000000203 mixture Substances 0.000 title claims abstract description 26
- 206010039073 rheumatoid arthritis Diseases 0.000 title claims abstract description 24
- 229940079593 drug Drugs 0.000 claims abstract description 23
- 239000000463 material Substances 0.000 claims abstract description 3
- 229940126680 traditional chinese medicines Drugs 0.000 claims abstract description 3
- 238000001035 drying Methods 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 claims description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- 239000012141 concentrate Substances 0.000 claims description 8
- 239000000706 filtrate Substances 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 8
- 239000008213 purified water Substances 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 241000131808 Scolopendra Species 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 5
- 239000012567 medical material Substances 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 4
- 238000010992 reflux Methods 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 210000003734 kidney Anatomy 0.000 abstract description 18
- 210000004185 liver Anatomy 0.000 abstract description 14
- 208000002193 Pain Diseases 0.000 abstract description 10
- 230000000694 effects Effects 0.000 abstract description 6
- 239000008280 blood Substances 0.000 abstract description 5
- 210000004369 blood Anatomy 0.000 abstract description 5
- 238000002474 experimental method Methods 0.000 abstract description 5
- 230000003213 activating effect Effects 0.000 abstract description 3
- 241000258920 Chilopoda Species 0.000 abstract 1
- 241000123589 Dipsacus Species 0.000 abstract 1
- 241000208689 Eucommia ulmoides Species 0.000 abstract 1
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract 1
- 235000015512 Liquidambar formosana Nutrition 0.000 abstract 1
- 241000893545 Liquidambar formosana Species 0.000 abstract 1
- 241000195954 Lycopodium clavatum Species 0.000 abstract 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 abstract 1
- 235000011477 liquorice Nutrition 0.000 abstract 1
- 239000000796 flavoring agent Substances 0.000 description 7
- 235000019634 flavors Nutrition 0.000 description 7
- 210000001503 joint Anatomy 0.000 description 7
- 208000006820 Arthralgia Diseases 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 210000000952 spleen Anatomy 0.000 description 6
- 210000000988 bone and bone Anatomy 0.000 description 5
- 210000000811 metacarpophalangeal joint Anatomy 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 230000008961 swelling Effects 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 206010030113 Oedema Diseases 0.000 description 3
- 208000005392 Spasm Diseases 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- 206010003246 arthritis Diseases 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 210000000629 knee joint Anatomy 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 210000000878 metatarsophalangeal joint Anatomy 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 231100000614 poison Toxicity 0.000 description 3
- 230000035935 pregnancy Effects 0.000 description 3
- 210000000707 wrist Anatomy 0.000 description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 241000521257 Hydrops Species 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010027514 Metrorrhagia Diseases 0.000 description 2
- 208000025747 Rheumatic disease Diseases 0.000 description 2
- 206010067868 Skin mass Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 2
- 229960001259 diclofenac Drugs 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 210000002683 foot Anatomy 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 210000004247 hand Anatomy 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 210000001624 hip Anatomy 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 231100000862 numbness Toxicity 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 230000000552 rheumatic effect Effects 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 description 1
- SQUNAWUMZGQQJD-UHFFFAOYSA-N 1-(4-ethylphenyl)-2-methyl-3-(piperidin-1-yl)propan-1-one Chemical compound C1=CC(CC)=CC=C1C(=O)C(C)CN1CCCCC1 SQUNAWUMZGQQJD-UHFFFAOYSA-N 0.000 description 1
- XILVEPYQJIOVNB-UHFFFAOYSA-N 2-[3-(trifluoromethyl)anilino]benzoic acid 2-(2-hydroxyethoxy)ethyl ester Chemical compound OCCOCCOC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 XILVEPYQJIOVNB-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 206010002027 Amyotrophy Diseases 0.000 description 1
- 208000008822 Ankylosis Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 206010051728 Bone erosion Diseases 0.000 description 1
- 206010005963 Bone formation increased Diseases 0.000 description 1
- 206010065553 Bone marrow failure Diseases 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 206010061156 Finger deformity Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 206010019837 Hepatocellular injury Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 206010023198 Joint ankylosis Diseases 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 description 1
- 206010027336 Menstruation delayed Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- 206010028817 Nausea and vomiting symptoms Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 208000009921 Rheumatoid Nodule Diseases 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- 206010046910 Vaginal haemorrhage Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 210000000544 articulatio talocruralis Anatomy 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 208000037979 autoimmune inflammatory disease Diseases 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 235000019636 bitter flavor Nutrition 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000009266 disease activity Effects 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 210000001513 elbow Anatomy 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229960002565 eperisone Drugs 0.000 description 1
- 229960001493 etofenamate Drugs 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 208000017561 flaccidity Diseases 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000037308 hair color Effects 0.000 description 1
- 210000002478 hand joint Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000004394 hip joint Anatomy 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- 229940076263 indole Drugs 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000009916 joint effect Effects 0.000 description 1
- 230000008407 joint function Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 229960001929 meloxicam Drugs 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 229960004380 tramadol Drugs 0.000 description 1
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 210000003857 wrist joint Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/46—Eucommiaceae (Eucommia family), e.g. hardy rubber tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/648—Myriapods, e.g. centipedes or millipedes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/15—Preparation or pretreatment of starting material involving mechanical treatment, e.g. chopping up, cutting or grinding
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Botany (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Insects & Arthropods (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明属于医药技术领域,一种用于治疗类风湿性关节炎的中药组合物,由含有下列中药材制备而成:杜仲、独活、狗脊、路路通、续断、伸筋草、蜈蚣和甘草。经临床实验验证本发明中8味中药材配伍使用,可相互协调,发挥奇效,具补益肝肾、祛风除湿、活血通络止痛的作用。
Description
技术领域
本发明涉及医药技术领域,尤其涉及一种用于治疗类风湿性关节炎的中药及其制备方法。
背景技术
类风湿性关节炎又称类风湿,是一种慢性全身性炎症性疾病,以慢性、对称性、多滑膜关节炎和关节外病变为主要临床表现,属于自身免疫炎性疾病。该病好发于手、腕、足等小关节,反复发作,呈对称分布。早期有关节红肿热痛和功能障碍,晚期关节可出现不同程度的僵硬畸形,并伴有骨和骨骼肌的萎缩,极易致残。
其主要临床表现有:1晨起时时关节僵硬,活动后逐渐减轻,僵硬时间的长短是疾病活动的指标。2、关节疼痛、肿胀、僵硬,早期常有手部近侧指间关节梭形肿胀和掌指关节疼痛肿胀,足部外侧跖趾关节疼痛,大关节有积液,特别是膝关节,可累及滑膜关节。3、畸形,早期由于肌肉痉挛可发生轻度畸形;晚期则趋明显,如手指的鹅颈畸形,近侧指间关节过伸,远侧指间关节屈曲、掌指关节尺侧偏畸形、膝关节、屈曲畸形,髋关节屈曲畸形等。4、其他的症状表现皮下结节严重者可以伴有肌肉萎缩等。
常用西药有非甾体类消炎止痛药,例如吲哚美幸、布洛芬、双氯芬酸、美洛昔康;单纯止痛药有对乙酰氨基酚、曲马多;肌肉松弛剂如乙哌立松;激素类如倍他米松;软骨修复药物如硫酸软骨素、氨基葡萄糖;外用药中有双氯芬酸乳剂、依托芬那酯;局部注射药有透明质酸钠等。然西药虽然有较好的止痛作用,但该药毒性很大,已引起恶心呕吐、腹痛腹泻、肝细胞损害、骨髓抑制、脱发、呼吸抑制、胃肠不适、头痛、头晕、焦虑、皮疹及肾功能损害。激素类药物容易影响患者的血压、血糖、血脂及骨代谢,诱发或加重消化性溃疡。
中医理论认为,“肾为先天之本”,“肾生骨髓”,“其充在骨”。的生长、发育、强劲、衰弱与肾精盛衰关系密切,肾精充足则骨髓生化有源,骨骼得以滋养而强健有力;肾精亏虚则骨髓生化无源,骨骼失养而痿弱无力。故从肾着手治疗是根本大法之一。
发明内容
本发明提供了一种用于治疗类风湿性关节炎的中药组合物。
本发明是通过以下技术方案实现的:
一种用于治疗类风湿性关节炎的中药组合物,由含有下列中药材制备而成:
杜仲、独活、狗脊、路路通、续断、伸筋草、蜈蚣和甘草。
作为优选技术方案,本发明是通过以下技术方案实现的:
一种用于治疗类风湿性关节炎的中药组合物,由含有下列重量份的中药材制备而成:
作为优选地技术方案之一,本发明是通过以下技术方案实现的:
一种用于治疗类风湿性关节炎的中药组合物,由含有下列重量份的中药材制备而成:
作为优选地技术方案之二,本发明是通过以下技术方案实现的:
一种用于治疗类风湿性关节炎的中药组合物,由含有下列重量份的中药材制备而成:
作为优选地技术方案之三,本发明是通过以下技术方案实现的:
一种用于治疗类风湿性关节炎的中药组合物,由含有下列重量份的中药材制备而成:
本发明所用的原料药的药性如下:
杜仲:性味甘,温。归肝、肾经。补肝肾,强筋骨,安胎。用于肾虚腰痛,筋骨无力,妊娠漏血,胎动不安;高血压。
独活:性味辛、苦,微温。归肾、膀胱经。祛风除湿,通痹止痛。用于风寒湿痹,腰膝疼痛,少阴伏风头痛。
狗脊:性味苦、甘,温。归肝、肾经。补肝肾,强腰脊,祛风湿。用于腰膝酸软,下肢无力,风湿痹痛。
路路通:性味苦,平。归肝、肾经。祛风活络,利水通经。用于关节痹痛,麻木拘挛,水肿胀满,乳少经闭。
续断:性味苦、辛,微温。归肝、肾经。补肝肾,强筋骨,续折伤,止崩漏。用于腰膝酸软,风湿痹痛,崩漏,胎漏,跌扑损伤。
伸筋草:性味微苦、辛,温。归肝、脾、肾经。祛风除湿,舒筋活络。用于关节酸痛,屈伸不利。
蜈蚣:性味辛,温;有毒。归肝经。息风镇痉,功毒散结,通络止痛。用于小儿惊风,抽搐痉挛,中风口歪,半身不遂,破伤风,风湿顽痹,疮疡,瘰疬,毒蛇咬伤。
甘草:性味甘,平。归心、肺、脾、胃经。补脾益气,清热解毒,祛痰止咳,缓急止痛,调和诸药。用于脾胃虚弱,倦怠乏力,心悸气短,咳嗽痰多,脘腹、四肢挛急疼痛,痈肿疮毒,缓解药物毒性、烈性。
本发明还提了一种用于治疗类风湿关节炎中药组合物的制备方法:
(1)、分别称取杜仲、狗脊、路路通、续断、伸筋草、甘草,粉碎过20-40目筛,混匀;加入6-10倍重量的纯化水,浸泡6-24小时,回流煎煮2-4小时,过滤,再加入药材3-6倍重量的纯化水,回流煎煮1-3小时,过滤,合并滤液,浓缩干燥,粉碎过100目筛;
(2)、将步骤(1)的滤渣加5-10倍重量的浓度65-80%的乙醇,回流提取2次,每次1-2小时,过滤,合并滤液,浓缩干燥,粉碎过100目筛;
(3)、分别称取蜈蚣、独活,干燥粉碎,过100目筛;
(4)将步骤(1)、(2)和(3)所得细粉合并,混匀,灌装胶囊剂;或添加辅料,利用现代通用的中药制剂技术制成目前临床需要的成品剂型。
应当理解的是本发明中药组合物,还可以采用传统的水煎方法,制备汤剂服用。
经临床实验验证本发明中8味中药材配伍使用,可相互协调,发挥奇效,具补益肝肾、祛风除湿、活血通络止痛的作用,与现有技术相比,具有以下优点:
1.本发明中药组合物配伍精简,仅有8味药材组成。
2.疗程短,疗效好,临床治愈率高达50%以上,总有效率高达90%以上。
3.本发明中药组合物治愈患者,复发率低。
4.本发明中药组合物服药剂量远低于传统中药,且无任何毒副作用。
具体实施方式
以下通过具体实施方式的描述对本发明作进一步说明,但这并非是对本发明的限制,本领域技术人员根据本发明的基本思想,可以做出各种修改或改进,但是只要不脱离本发明的基本思想,均在本发明的范围之内。
实施例1
一种用于治疗类风湿性关节炎的中药组合物,由含有下列重量份的中药材制备而成:
制备方法:
(1)、分别称取杜仲、狗脊、路路通、续断、伸筋草、甘草,粉碎过20目筛,混匀;加入8倍重量的纯化水,浸泡12小时,回流煎煮2小时,过滤,再加入药材6倍重量的纯化水,回流煎煮1小时,过滤,合并滤液,浓缩干燥,粉碎过100目筛。
(2)、将步骤(1)的滤渣加6倍重量的浓度78%的乙醇,回流提取2次,每次2小时,过滤,合并滤液,浓缩干燥,粉碎过100目筛。
(3)、分别称取蜈蚣、独活,干燥粉碎,过100目筛。
(4)将步骤(1)、(2)和(3)所得细粉合并,混匀,灭菌,灌装0号胶囊。
实施例2
一种用于治疗类风湿性关节炎的中药组合物,由含有下列重量份的中药材制备而成:
制备方法:
(1)、分别称取杜仲、狗脊、路路通、续断、伸筋草、甘草,粉碎过20目筛,混匀;加入8倍重量的纯化水,浸泡12小时,回流煎煮2小时,过滤,再加入药材6倍重量的纯化水,回流煎煮1小时,过滤,合并滤液,浓缩干燥,粉碎过100目筛。
(2)、将步骤(1)的滤渣加6倍重量的浓度70%的乙醇,回流提取2次,每次2小时,过滤,合并滤液,浓缩干燥,粉碎过100目筛。
(3)、分别称取蜈蚣、独活,干燥粉碎,过100目筛。
(4)将步骤(1)、(2)和(3)所得细粉合并,混匀,灭菌,灌装0号胶囊。
实施例3
一种用于治疗类风湿性关节炎的中药组合物,由含有下列重量份的中药材制备而成:
制备方法:
同实施例1。
实施例4
一种用于治疗类风湿性关节炎的中药组合物,由含有下列重量份的中药材制备而成:
制备方法:
同实施例1。
5.本发明治疗类风湿性关节炎的中药组合物的毒性实验
5.1本发明动物急性毒性试验
药物:本发明实施例1制备的药物细粉。
试验动物:普通级NIH小鼠12只,体重18g±2g,雌雄各半。
方法与结果:
1)药物配制:取实施例1的药物,用含2%阿拉伯树胶的生理盐水配至200g/L悬液:
2)实验采用灌胃给药方式。一次性给药,容积2ml/100g体重,密切观察8h并作记录,继续观察7d;
3)实验结果:7d中小鼠无死亡,行为活泼,摄食量如常,毛色光亮无疏松污,无惊厥嗜唾,眼、口、鼻、耳及肛周无异常分泌物,无断尾烂趾。选择5只处死,肉眼所见:心、肝、肺、胃内及胸腺等重要脏器,未见异常改变。
2、本发明动物长期毒性试验
药物:本发明实施例1制备的药物细粉。
动物:普通级SD大鼠24只,体重200g±10g,雌雄各半,随机分为3组。
方法与结果:
1)药物配制:分高、中、低三个剂量组,分别为临床用药量的300、150、75倍,用含2%阿拉伯树胶的生理盐水1:1混合;
2)实验采用灌胃给药方式,连续给药90天,观察动物全身毒性反应及严重程度,处死后按操作规程检查各部位,并进行血液学,ALT、BUN及心、肝、脾、肺、肾、胃等主要脏器的病理学检查;
3)实验结果:长期经口给药,高、中、低三个剂量组动物未出现毒性反应。发育良好。肉眼外观及主要脏器未见异常。外周血象及血清ALT、BUN与对照组比较无病理性改变。病理报告心、肝、脾、肺、肾、胃等均未有意义的改变,认为经病理证实对动物无中毒表现。
以上实验表明,本发明中药安全,无毒副作用。
6.临床资料:
6.1、病例选择
临床随机选择某市医院86例患者,其中男32例,女54例,年龄38-60岁,平均48.5±5.8岁,病程6个月-10年,平均4.0±2.8年。
5.2、诊断标准
所有病例均参照美国风湿病学会1987年制定的诊断标准拟定。该标准列举了7项临床及实验室特征:
①晨僵:关节内或关节周围晨僵,每日持续至少1h,持续至少6周。
②3个或3个以上关节炎;14个关节区中至少有3个同时出现肿胀或积液(不是单纯的骨质增生)持续至少6周。这14个关节区是:双侧近端指间关节、掌指关节、腕、肘、膝、踝和跖趾关节。
③手部关节关节炎:腕、掌指关节和近端指间关节至少1处肿胀,持续至少6周。
④对称性关节炎:身体双侧相同关节区同时受累(近端指间关节和(或)掌指关节和(或)跖趾关节区受累时可不是完全对称)持续至少6周。
⑤类风湿结节:关节伸侧、关节周围或骨突出部位的皮下结节。
⑥类风湿因子:阳性。
⑦影像学改变:手及腕部前后位摄片有骨质侵蚀或骨质疏松。
符合以上7项中的4项者便可诊断。
排除病例:
①合并严重的心脑血管病者;
②严重肝肾功能不全者;
③妊娠或哺乳期妇女者;
④对本药过敏者;
⑤正在服用激素或1月内曾服用激素者;
⑥关节功能IV级的患者,
⑦未按规定用药或资料不全等影响疗效或安全性判断者。
6.3、疗效标准
参照《中药新药临床研究指导原则》中有关疗效标准拟定。
治愈:症状全部消失,关节功能活动恢复正常,主要理化检查指标正常。
显效:全部症状消失或主要症状消失,关节功能基本恢复,理化检查指标基本正常,能正常工作和劳动。
有效:主要症状基本消失,主要关节功能基本恢复或明显改善,主要理化检查指标有所改善,生活从不能自理转为能够自理,或失去的工作劳动能力有所恢复。
无效:临床和体征及主要理化检查指标无改变。
6.4、治疗方法
口服本发明实施例1制备的胶囊剂,每次4粒,每天3次。2周为1疗程。
6.5、治疗结果
三个疗程后治疗结果为:治愈44例(51.2%),显效28例(32.5%),有效10例(11.6%),无效4例(4.7%),总有效率95.3%。
六个疗程后治疗结果为:治愈69例(80.2%),显效10例(11.6%),有效3例(3.5%),无效4例(4.7%),总有效率95.3%(最初三个疗程的治疗后有4例患者无效,没有继续服药治疗)。
所有达到临床治愈患者,药量减半,继续巩固治疗3个疗程。
6.6、复发情况
停药半年后对分别对69例临床治愈患者进行回访,复发3例,复发率仅为4.3%,远远低于常规西药治疗停药后的复发率。
尽管已经示出和描述了本发明的实施例,对于本领域的普通技术人员而言,可以理解在不脱离本发明的原理和精神的情况下可以对这些实施例进行多种变化、修改、替换和变型,本发明的范围由所附权利要求及其等同物限定。
Claims (6)
1.一种用于治疗类风湿性关节炎的中药组合物,其特征在于,由含有下列中药材制备而成:
杜仲、独活、狗脊、路路通、续断、伸筋草、蜈蚣和甘草。
2.如权利要求1所述的一种用于治疗类风湿性关节炎的中药组合物,其特征在于,由含有下列重量份的中药材制备而成:
3.如权利要求1所述的一种用于治疗类风湿性关节炎的中药组合物,其特征在于,由含有下列重量份的中药材制备而成:
4.如权利要求1所述的一种用于治疗类风湿性关节炎的中药组合物,其特征在于,由含有下列重量份的中药材制备而成:
5.如权利要求1所述的一种用于治疗类风湿性关节炎的中药组合物,其特征在于,由含有下列重量份的中药材制备而成:
6.如权利要求1-5所述的一种用于治疗类风湿性关节炎的中药组合物,其特征在于,其制备方法包含以下步骤:
(1)分别称取杜仲、狗脊、路路通、续断、伸筋草、甘草,粉碎过20-40目筛,混匀;加入6-10倍重量的纯化水,浸泡6-24小时,回流煎煮2-4小时,过滤,再加入药材3-6倍重量的纯化水,回流煎煮1-3小时,过滤,合并滤液,浓缩干燥,粉碎过100目筛;
(2)将步骤(1)的滤渣加5-10倍重量的浓度65-80%的乙醇,回流提取2次,每次1-2小时,过滤,合并滤液,浓缩干燥,粉碎过100目筛;
(3)分别称取蜈蚣、独活,干燥粉碎,过100目筛;
(4)将步骤(1)、(2)和(3)所得细粉合并,混匀,灌装胶囊剂;或添加辅料,利用现代通用的中药制剂技术制成目前临床需要的成品剂型。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510046858.6A CN104523817A (zh) | 2015-01-30 | 2015-01-30 | 一种用于治疗类风湿性关节炎的中药组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510046858.6A CN104523817A (zh) | 2015-01-30 | 2015-01-30 | 一种用于治疗类风湿性关节炎的中药组合物 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN104523817A true CN104523817A (zh) | 2015-04-22 |
Family
ID=52839573
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510046858.6A Pending CN104523817A (zh) | 2015-01-30 | 2015-01-30 | 一种用于治疗类风湿性关节炎的中药组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104523817A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104840516A (zh) * | 2015-05-25 | 2015-08-19 | 安徽科技学院 | 一种治疗类风湿性关节炎的中药冲剂及其生产方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100330215A1 (en) * | 2003-01-09 | 2010-12-30 | Bioactives, Inc. | Methods of Administering Anti-Inflammatory Cyclooxygenase-2 Selective Inhibitors |
CN102670864A (zh) * | 2012-06-01 | 2012-09-19 | 山东卫康生物医药科技有限公司 | 治疗心脑血管疾病和糖尿病的抗氧化功能的药物组合物 |
CN104013732A (zh) * | 2013-03-01 | 2014-09-03 | 陕西省食品药品检验所 | 一种治疗类风湿病的软胶囊 |
-
2015
- 2015-01-30 CN CN201510046858.6A patent/CN104523817A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100330215A1 (en) * | 2003-01-09 | 2010-12-30 | Bioactives, Inc. | Methods of Administering Anti-Inflammatory Cyclooxygenase-2 Selective Inhibitors |
CN102670864A (zh) * | 2012-06-01 | 2012-09-19 | 山东卫康生物医药科技有限公司 | 治疗心脑血管疾病和糖尿病的抗氧化功能的药物组合物 |
CN104013732A (zh) * | 2013-03-01 | 2014-09-03 | 陕西省食品药品检验所 | 一种治疗类风湿病的软胶囊 |
Non-Patent Citations (1)
Title |
---|
高学敏等: "《临床中药学》", 31 January 2006 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104840516A (zh) * | 2015-05-25 | 2015-08-19 | 安徽科技学院 | 一种治疗类风湿性关节炎的中药冲剂及其生产方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1161147C (zh) | 一种治疗骨关节疾病的口服中药 | |
CN100493566C (zh) | 一种内服治疗痛风的中药组合物 | |
CN101284114A (zh) | 治疗风湿和类风湿疾病的药物 | |
CN102475868B (zh) | 一种风湿药酒 | |
CN104491167B (zh) | 一种用于治疗类风湿性关节炎的中药及其制备方法 | |
CN104000890B (zh) | 调和肝脾、祛风除湿、养血止痹痛的中药 | |
CN101912536B (zh) | 一种治疗风湿类风湿的药物组合物 | |
CN102342983A (zh) | 一种治疗腰腿疼痛的中药组合物及其制剂的制备方法 | |
CN101721495B (zh) | 一种治疗风湿性关节炎的中草药酒 | |
CN101095730A (zh) | 一种治疗风湿类风湿性关节炎的药物 | |
CN104161805B (zh) | 一种治疗股骨头坏死的中药及制备方法 | |
CN104523817A (zh) | 一种用于治疗类风湿性关节炎的中药组合物 | |
CN102552443B (zh) | 一种治疗类风湿性关节炎的中药组合物及其制备方法 | |
CN103127458A (zh) | 一种治疗骨关节肌肉疼痛的药物 | |
CN103585483B (zh) | 一种治疗膝骨性关节病的中药组合物及其制备方法 | |
CN106362066A (zh) | 一种治疗风湿类风湿性疾病的药酒及其制备方法 | |
CN106540229A (zh) | 一种治疗寒性痛病的外用药酒及其制备方法 | |
CN102240351A (zh) | 一种治疗关节炎骨质增生椎间盘突出颈椎病的中药药物 | |
CN102512560A (zh) | 一种治疗痹症的中药组合物 | |
CN101502604B (zh) | 一种治疗风湿病的中草药制剂 | |
CN104857440A (zh) | 一种治疗肾虚血瘀型中晚期股骨头坏死的中药及其制备方法 | |
CN1615968A (zh) | 一种治疗跌打损伤的中药制剂接骨散 | |
CN115177690B (zh) | 一种用于治疗骨性关节炎的中药组合物及其制备方法 | |
CN104547086A (zh) | 一种治疗类风湿性关节炎的中药组合物 | |
CN101732450B (zh) | 一种治疗风湿性关节炎的药酒 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150422 |
|
RJ01 | Rejection of invention patent application after publication |